Followers | 223 |
Posts | 11552 |
Boards Moderated | 1 |
Alias Born | 07/07/2008 |
Monday, February 05, 2018 11:31:27 AM
jcamp212 Tuesday, 01/23/18 12:14:06 PM
Re: None
Post # of 4910
Analyst Reiterates 'Buy' Rating on GW Pharma, Sees >10% Upside
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/01/23/GWPH-Analyst-Reiterates-Buy-Rating-on-GW-Pharma-Sees-10-Percent-Upside
Leerink Swann's Paul Matteis just reiterated his 'buy' rating on shares of GW Pharmaceuticals Plc (NASDAQ:GWPH) alongside a price target of $153.00 per share. GW Pharma currently has an average price target of $175.00 per share, and out of the four analysts we track that cover GWPH, Matteis's price target is the highest.
With a last trade price of $138.18 for shares of GW Pharma, this price target represents over 10% potential upside.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM